JP2022544536A5 - - Google Patents

Info

Publication number
JP2022544536A5
JP2022544536A5 JP2022509051A JP2022509051A JP2022544536A5 JP 2022544536 A5 JP2022544536 A5 JP 2022544536A5 JP 2022509051 A JP2022509051 A JP 2022509051A JP 2022509051 A JP2022509051 A JP 2022509051A JP 2022544536 A5 JP2022544536 A5 JP 2022544536A5
Authority
JP
Japan
Prior art keywords
substituted
heteroaralkyl
aralkyl
heteroaryl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544536A (ja
JP7583027B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046269 external-priority patent/WO2021034627A1/en
Publication of JP2022544536A publication Critical patent/JP2022544536A/ja
Publication of JP2022544536A5 publication Critical patent/JP2022544536A5/ja
Application granted granted Critical
Publication of JP7583027B2 publication Critical patent/JP7583027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509051A 2019-08-16 2020-08-14 プロテアソームのコア粒子の低分子刺激物質 Active JP7583027B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962887732P 2019-08-16 2019-08-16
US62/887,732 2019-08-16
PCT/US2020/046269 WO2021034627A1 (en) 2019-08-16 2020-08-14 Small molecule stimulators of the core particle of the proteasome

Publications (3)

Publication Number Publication Date
JP2022544536A JP2022544536A (ja) 2022-10-19
JP2022544536A5 true JP2022544536A5 (enExample) 2023-06-15
JP7583027B2 JP7583027B2 (ja) 2024-11-13

Family

ID=74659522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509051A Active JP7583027B2 (ja) 2019-08-16 2020-08-14 プロテアソームのコア粒子の低分子刺激物質

Country Status (5)

Country Link
US (1) US20220267280A1 (enExample)
EP (1) EP4013405A4 (enExample)
JP (1) JP7583027B2 (enExample)
CN (1) CN114222573A (enExample)
WO (1) WO2021034627A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620881A (zh) * 2021-08-12 2021-11-09 浙江禾本科技股份有限公司 一种1-[2-(2,4-二氯苯基)-2羟基乙基]-1h咪唑的合成方法
EP4147723A1 (en) 2021-09-09 2023-03-15 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
EP4398941A1 (en) 2021-09-09 2024-07-17 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
WO2025219559A1 (en) 2024-04-18 2025-10-23 Booster Therapeutics Gmbh Pyrrolidine compounds as proteasome stimulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
US3991202A (en) * 1974-01-31 1976-11-09 Janssen Pharmaceutica N.V. Imidazolium salts
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
NZ328607A (en) * 1996-09-09 1999-08-30 Hoffmann La Roche Heterocyclically substituted n-benzyl-azolium derivatives and fungicidal compositions
EP0829478A3 (en) * 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
WO2004022546A1 (ja) * 2002-09-04 2004-03-18 Keimei Oh ジャスモン酸の生合成を阻害する物質
EP1896406A2 (en) * 2005-06-14 2008-03-12 Shering Corporation The preparation and use of compounds as protease inhibitors
BRPI0904249B1 (pt) 2009-08-28 2018-03-06 Biolab Sanus Farmacêutica Ltda. Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica
CA2990686A1 (en) * 2015-07-16 2017-01-19 Amari Biopharma, Inc. Methods of preventing toxicity of platinum drugs comprising administering an oct monitor

Similar Documents

Publication Publication Date Title
JP2022544536A5 (enExample)
JP2020169171A5 (enExample)
JP2018519302A5 (enExample)
JP2017524025A5 (enExample)
JP2019518050A5 (enExample)
JP2023531311A5 (enExample)
JP2010501003A5 (enExample)
JP2021526133A5 (enExample)
JP2021501754A5 (enExample)
JP2022506111A5 (enExample)
JP2022545633A5 (enExample)
JP2017519781A5 (enExample)
JP2008505157A5 (enExample)
JP2020503009A5 (enExample)
JP2020503010A5 (enExample)
JP2019526596A5 (enExample)
JP2018199694A5 (enExample)
JP2022512736A5 (enExample)
JP2012532136A5 (enExample)
JP2014500295A5 (enExample)
JP2011525927A5 (enExample)
JP2015500833A5 (enExample)
JP2015509535A5 (enExample)
JP2019527724A5 (enExample)
JP2005511699A5 (enExample)